AngioDynamics Inc (ANGO) shareholders
ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 12/306% below fair value
$11.98−0.44 (-3.50%)
Close on Nov 12, 2026Market cap $504.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.0%
38M of 42M shares
Institutional holders
162
31 new, 15 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $654.69K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Divisadero Street Capital Management, LP Joint filing with William Zolezzi (8.40%), Divisadero Street Capital, LLC (8.40%) and 2 more | 3,395,430 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (7.70%), Point72 Capital Advisors, Inc. (7.70%) | 3,181,829 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 2,918,422 | 7.20% | 13G (passive) amendment | Mar 31, 2025 |
| Systematic Financial Management LP | 2,508,295 | 6.10% | 13G (passive) | Dec 31, 2025 |
| Kevin Kotler | 2,421,526 | 5.90% | 13G (passive) | Jan 6, 2026 |
| William Zolezzi Joint filing with Divisadero Street Capital Management, LP (5.30%), Divisadero Street Partners, L.P. (5.30%) and 2 more | 2,137,081 | 5.30% | 13G (passive) | Jun 2, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (5.20%), Steven A. Cohen (5.20%) | 2,120,202 | 5.20% | 13G (passive) | Jul 16, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (5.16%) | 2,094,000 | 5.16% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANGO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,803,232 | 9.04% | $49.48M | +117,328 | 0.00% |
| Point72 Asset Management, L.P. | 3,062,517 | 7.28% | $39.84M | −119,312 | 0.04% |
| Systematic Financial Management LP | 2,640,214 | 6.28% | $34.35M | +186,513 | 0.68% |
| Armistice Capital, LLC | 2,198,000 | 5.23% | $28.60M | +329,000 | 0.35% |
| Royce & Associates LP | 1,969,835 | 4.68% | $25.63M | +440,884 | 0.21% |
| Broadfin Holdings LLC | 1,818,533 | 4.32% | $23.66M | −250,800 | 100.00% |
| Vanguard Capital Management LLC | 1,694,716 | 4.03% | $22.05M | −32,104 | 0.00% |
| Weber Capital Management LLC /Adv | 1,356,602 | 3.23% | $17.65M | −16,547 | 15.02% |
| Nuveen, LLC | 1,199,358 | 2.85% | $15.60M | −16,807 | 0.00% |
| Geode Capital Management, LLC | 1,020,658 | 2.43% | $13.28M | +35,235 | 0.00% |
| Dimensional Fund Advisors LP | 969,497 | 2.31% | $12.61M | +20,682 | 0.00% |
| State Street Corp | 958,167 | 2.28% | $12.47M | −375,691 | 0.00% |
| Segall Bryant & Hamill, LLC | 926,711 | 2.20% | $12.06M | −39,254 | 0.14% |
| Bastion Asset Management Inc. | 923,270 | 2.20% | $10.78M | −389,732 | 3.66% |
| Pier Capital, LLC | 806,678 | 1.92% | $10.49M | +9,982 | 1.39% |
| Millennium Management LLC | 783,125 | 1.86% | $10.19M | +138,448 | 0.00% |
| Renaissance Technologies LLC | 733,883 | 1.75% | $9.55M | −69,400 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 692,534 | 1.65% | $9.01M | −65,916 | 0.00% |
| Paradigm Capital Management Inc/Ny | 671,200 | 1.60% | $8.73M | −47,000 | 0.24% |
| Aqr Capital Management LLC | 589,157 | 1.40% | $7.66M | +337,643 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 38M | 91.0% | 31 / 56 | 56 / 15 | 3M | 4M |
| Q1 2026 | 147 | 39M | 92.0% | 19 / 54 | 57 / 36 | 8M | 4M |
| Q4 2025 | 167 | 39M | 92.5% | 36 / 55 | 53 / 11 | 7M | 7M |
| Q3 2025 | 144 | 39M | 93.1% | 23 / 55 | 47 / 29 | 5M | 3M |
| Q2 2025 | 150 | 37M | 87.8% | 19 / 55 | 53 / 22 | 6M | 4M |
| Q1 2025 | 154 | 35M | 84.3% | 35 / 46 | 58 / 15 | 9M | 6M |
| Q4 2024 | 135 | 33M | 79.4% | 22 / 52 | 45 / 25 | 6M | 5M |
| Q3 2024 | 138 | 33M | 78.1% | 21 / 57 | 37 / 21 | 10M | 4M |
| Q2 2024 | 140 | 33M | 78.4% | 23 / 45 | 58 / 17 | 5M | 11M |
| Q1 2024 | 135 | 39M | 93.3% | 15 / 49 | 58 / 28 | 6M | 5M |
| Q4 2023 | 150 | 38M | 91.3% | 29 / 50 | 54 / 33 | 9M | 6M |
| Q3 2023 | 154 | 35M | 84.2% | 27 / 69 | 44 / 28 | 10M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
172 funds held ANGO in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANGO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,173,227 | 2.79% | $15.26M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 973,144 | 2.31% | $12.66M | 0.02% | Jun 30, 2026 |
| Royce Small-Cap Opportunity Fund | 707,398 | 1.68% | $9.20M | 0.65% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 626,469 | 1.49% | $8.15M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 484,796 | 1.15% | $6.31M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 406,661 | 0.97% | $6.01M | 0.02% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 382,490 | 0.91% | $5.66M | 0.14% | Jul 31, 2026 |
| First Eagle Small Cap Opportunity Fund | 310,729 | 0.74% | $4.60M | 0.16% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 261,136 | 0.62% | $3.40M | 0.02% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 224,372 | 0.53% | $2.58M | 0.05% | May 29, 2026 |
| Fidelity Extended Market Index Fund | 214,612 | 0.51% | $2.46M | 0.01% | May 31, 2026 |
| Sbh Small Cap Value Fund | 205,492 | 0.49% | $2.67M | 0.60% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 203,599 | 0.48% | $2.34M | 0.01% | May 31, 2026 |
| Paradigm Micro-Cap Fund | 197,900 | 0.47% | $2.57M | 1.40% | Jun 30, 2026 |
| iShares U.S. Medical Devices ETF | 193,491 | 0.46% | $2.52M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Honroth | President and CEO, Director | 101,193 | 0.24% | Nov 4, 2026 |
| James C. Clemmer | President and CEO, Director | 862,448 | 2.05% | Jul 24, 2026 |
| Stephen A. Trowbridge | EVP and CFO | 280,461 | 0.67% | Oct 30, 2026 |
| Warren Nighan JR | SVP Quality and Regulatory | 64,745 | 0.15% | Jul 31, 2026 |
| Chad Thomas Campbell | SVP/GM, Vascular Access | 111,006 | 0.26% | Jul 24, 2026 |
| Laura Piccinini | SVP International | 81,929 | 0.19% | Jul 24, 2026 |
| Lawrence T. Weiss | SVP, Chief Legal Officer | 112,618 | 0.27% | Jul 22, 2026 |
| Karen A. Licitra | Director | 102,322 | 0.24% | Jul 22, 2026 |
| Howard W. Donnelly | Director | 178,938 | 0.43% | Jul 22, 2026 |
| Lorinda Burgess | Director | 67,144 | 0.16% | Jul 22, 2026 |
| Eileen O'Shea Auen | Director | 116,605 | 0.28% | Jul 22, 2026 |
| Jan Stern Reed | Director | 116,921 | 0.28% | Jul 22, 2026 |
| Michael E. Tarnoff | Director | 95,265 | 0.23% | Jul 22, 2026 |
| Wesley Johnson | Director | 155,425 | 0.37% | Jul 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric Honroth President and CEO, Director | Nov 2, 2026 | Award | +38,265 | – | – | 101,193 |
| Eric Honroth President and CEO, Director | Nov 2, 2026 | Award | +62,928 | – | – | 62,928 |
| Stephen A. Trowbridge EVP and CFO | Oct 29, 2026 | Sale | −23,615 | $12.27 | $289.76K | 280,461 |
| Stephen A. Trowbridge EVP and CFO | Oct 28, 2026 | Sale | −1,720 | $12.17 | $20.93K | 304,076 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 30, 2026 | Sale | −23,370 | $14.72 | $344.01K | 64,745 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 22, 2026 | Option exercise | +6,466 | – | – | 111,006 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 22, 2026 | Tax withholding | −2,330 | $13.82 | $32.20K | 108,676 |
| James C. Clemmer President and CEO, Director | Jul 22, 2026 | Tax withholding | −26,728 | $13.82 | $369.38K | 862,448 |
| James C. Clemmer President and CEO, Director | Jul 22, 2026 | Option exercise | +52,358 | – | – | 889,176 |
| Laura Piccinini SVP International | Jul 22, 2026 | Tax withholding | −4,506 | $13.82 | $62.27K | 81,929 |
| Laura Piccinini SVP International | Jul 22, 2026 | Option exercise | +8,047 | – | – | 86,435 |
| Stephen A. Trowbridge EVP and CFO | Jul 22, 2026 | Option exercise | +16,296 | – | – | 314,115 |
| Stephen A. Trowbridge EVP and CFO | Jul 22, 2026 | Tax withholding | −8,319 | $13.82 | $114.97K | 305,796 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 22, 2026 | Tax withholding | −1,671 | $13.82 | $23.09K | 88,115 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 22, 2026 | Option exercise | +5,694 | – | – | 89,786 |
| Stephen A. Trowbridge EVP and CFO | Jul 20, 2026 | Tax withholding | −717 | $13.71 | $9.83K | 244,562 |
| James C. Clemmer President and CEO, Director | Jul 20, 2026 | Tax withholding | −4,223 | $13.71 | $57.90K | 836,818 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 20, 2026 | Tax withholding | −251 | $13.71 | $3.44K | 66,126 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 20, 2026 | Tax withholding | −359 | $13.71 | $4.92K | 88,459 |
| Laura Piccinini SVP International | Jul 20, 2026 | Tax withholding | −616 | $13.71 | $8.45K | 58,528 |
| James C. Clemmer President and CEO, Director | Jul 19, 2026 | Tax withholding | −11,764 | $13.51 | $158.93K | 841,528 |
| James C. Clemmer President and CEO, Director | Jul 19, 2026 | Tax withholding | −487 | $13.51 | $6.58K | 841,041 |
| Stephen A. Trowbridge EVP and CFO | Jul 17, 2026 | Tax withholding | −3,510 | $13.51 | $47.42K | 245,279 |
| James C. Clemmer President and CEO, Director | Jul 17, 2026 | Tax withholding | −10,649 | $13.51 | $143.87K | 853,292 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 17, 2026 | Tax withholding | −1,373 | $13.51 | $18.55K | 66,377 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 17, 2026 | Tax withholding | −1,112 | $13.51 | $15.02K | 88,818 |
| Laura Piccinini SVP International | Jul 17, 2026 | Tax withholding | −3,074 | $13.51 | $41.53K | 59,144 |
| Stephen A. Trowbridge EVP and CFO | Jul 16, 2026 | Tax withholding | −7,840 | $14.14 | $110.86K | 248,789 |
| Lawrence T. Weiss SVP, Chief Legal Officer | Jul 16, 2026 | Tax withholding | −2,267 | $14.14 | $32.06K | 91,330 |
| James C. Clemmer President and CEO, Director | Jul 16, 2026 | Tax withholding | −18,588 | $14.14 | $262.83K | 863,941 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 16, 2026 | Tax withholding | −2,153 | $14.14 | $30.44K | 67,750 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 16, 2026 | Tax withholding | −2,367 | $14.14 | $33.47K | 89,930 |
| Laura Piccinini SVP International | Jul 16, 2026 | Tax withholding | −4,538 | $14.14 | $64.17K | 62,218 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 15, 2026 | Award | +17,966 | – | – | 84,092 |
| Eileen O'Shea Auen Director | Jul 15, 2026 | Award | +11,887 | – | – | 116,605 |
| Lorinda Burgess Director | Jul 15, 2026 | Award | +11,887 | – | – | 67,144 |
| Howard W. Donnelly Director | Jul 15, 2026 | Award | +11,887 | – | – | 178,938 |
| Jan Stern Reed Director | Jul 15, 2026 | Award | +11,887 | – | – | 116,921 |
| Stephen A. Trowbridge EVP and CFO | Jul 15, 2026 | Award | +53,257 | – | – | 297,819 |
| Karen A. Licitra Director | Jul 15, 2026 | Award | +11,887 | – | – | 102,322 |
| Wesley Johnson Director | Jul 15, 2026 | Award | +11,887 | – | – | 155,425 |
| Laura Piccinini SVP International | Jul 15, 2026 | Award | +19,860 | – | – | 78,388 |
| Lawrence T. Weiss SVP, Chief Legal Officer | Jul 15, 2026 | Award | +21,288 | – | – | 112,618 |
| Michael E. Tarnoff Director | Jul 15, 2026 | Award | +11,887 | – | – | 95,265 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 15, 2026 | Award | +16,081 | – | – | 104,540 |
| Lawrence T. Weiss SVP, Chief Legal Officer | Oct 21, 2025 | Buy | +10,000 | $11.81 | $118.10K | 93,597 |
| Stephen A. Trowbridge EVP and CFO | Oct 13, 2025 | Buy | +890 | $11.16 | $9.93K | 256,629 |
| James C. Clemmer President and CEO, Director | Oct 9, 2025 | Buy | +10,000 | $11.15 | $111.50K | 882,529 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 21, 2025 | Tax withholding | −277 | $8.99 | $2.49K | 69,903 |
| Stephen A. Trowbridge EVP and CFO | Jul 21, 2025 | Tax withholding | −667 | $8.99 | $6.00K | 255,739 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 21, 2025 | Tax withholding | −395 | $8.99 | $3.55K | 92,297 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 20, 2025 | Tax withholding | −251 | $8.69 | $2.18K | 70,180 |
| Stephen A. Trowbridge EVP and CFO | Jul 20, 2025 | Tax withholding | −717 | $8.69 | $6.23K | 256,406 |
| Laura Piccinini SVP International | Jul 20, 2025 | Tax withholding | −616 | $8.69 | $5.35K | 66,756 |
| James C. Clemmer President and CEO, Director | Jul 20, 2025 | Tax withholding | −2,982 | $8.69 | $25.91K | 876,202 |
| James C. Clemmer President and CEO, Director | Jul 20, 2025 | Tax withholding | −3,673 | $8.99 | $33.02K | 872,529 |
| Chad Thomas Campbell SVP/GM, Vascular Access | Jul 20, 2025 | Tax withholding | −359 | $8.69 | $3.12K | 92,692 |
| Warren Nighan JR SVP Quality and Regulatory | Jul 19, 2025 | Tax withholding | −735 | $8.69 | $6.39K | 70,431 |
| Stephen A. Trowbridge EVP and CFO | Jul 19, 2025 | Tax withholding | −2,585 | $8.69 | $22.46K | 257,123 |
| Laura Piccinini SVP International | Jul 19, 2025 | Tax withholding | −1,983 | $8.69 | $17.23K | 67,372 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
5.06%
2M shares short
Days to cover
2.9
At 1M shares a day
Change since last report
+4.5%
From 2M shares
Short volume, 20 days
50.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AngioDynamics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,288 shares on Aug 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen A. Trowbridge Officer | Oct 29, 2026 | 23,615 | $289.72K | Oct 29, 2026 | Restricted Stock |
| Warren Nighan JR Officer | Jul 30, 2026 | 23,370 | $344.00K | Jul 30, 2026 | Restricted Stock |
| Warren Nighan JR Officer | Jan 16, 2025 | 4,060 | $49.98K | Jan 16, 2025 | PERFORMANCE SHARES |
See a number that looks wrong?